Savvy Updates, 9/16/24: Abbott Libre 3 Recall, FDA Clears Modular Medical PODD1 Pump, Air Flight Can Disrupt Pump Insulin Delivery, Roche to Launch Accu-Chek Smartguide CGM, Ozempic/Mounjaro & Metformin, Abvance Therapeutics Gets $3.9M for Novel Insulin & Glucagon Formulation, Dexcom CGM Worn in Space for 1st Time, Drug Interactions with GLP-1 Agonists & SGLT-2 Inhibitors, Semaglutide Impact on Body Composition, 4 largest PBMs Control 70% of Prescription Drug Market, Banana Leaves as New Source of Protein Powder

Savvy Updates, 9/16/24: Abbott Libre 3 Recall, FDA Clears Modular Medical PODD1 Pump, Air Flight Can Disrupt Pump Insulin Delivery, Roche to Launch Accu-Chek Smartguide CGM, Ozempic/Mounjaro & Metformin, Abvance Therapeutics Gets $3.9M for Novel Insulin & Glucagon Formulation, Dexcom CGM Worn in Space for 1st Time, Drug Interactions with GLP-1 Agonists & SGLT-2 Inhibitors, Semaglutide Impact on Body Composition, 4 largest PBMs Control 70% of Prescription Drug Market, Banana Leaves as New Source of Protein Powder

Sep 14, 2024 | Diabetes Business, Featured, Foods, Research News, Technology Updates

Continuous Glucose Monitoring (CGM) Sensor Recall: Abbott Diabetes Care Inc Issues Recall for Certain FreeStyle Libre 3 Sensors due to Risk for Inaccurate High Glucose Readings posted by FDA.gov/medical-devices, 5 September 2024. This recall involves removing...
Savvy Updates, 10/2/23: Senseonics Completes 365-Day Study, SiBionics CGM & GiveAway, Abvance’s Coformulation of Insulin & Glucagon, Period Cravings & Insulin Sensitivies, Ozempic Reduces Insulin Needs in T1Ds, CVS Caremark Sued By Independent Pharmacy for Antitrust Violations

Savvy Updates, 10/2/23: Senseonics Completes 365-Day Study, SiBionics CGM & GiveAway, Abvance’s Coformulation of Insulin & Glucagon, Period Cravings & Insulin Sensitivies, Ozempic Reduces Insulin Needs in T1Ds, CVS Caremark Sued By Independent Pharmacy for Antitrust Violations

Oct 2, 2023 | Diabetes Business, Featured, Foods, LOOPing, Research News, Technology Updates

Senseonics completes 365-day CGM study cohort by Sean Whooley for DrugDeliveryBusiness.com, 26 September 2023. Senseonics announced that it completed its ENHANCE pivotal clinical study adult cohort for its 365-day Eversense CGM.  The study evaluates the year-long...
Skip to content